WCM Investment Management LLC Sells 68,753 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

WCM Investment Management LLC lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 48.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,094 shares of the company's stock after selling 68,753 shares during the quarter. WCM Investment Management LLC owned approximately 0.06% of Vaxcyte worth $5,911,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock valued at $1,247,954,000 after buying an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after buying an additional 485,436 shares in the last quarter. State Street Corp grew its stake in shares of Vaxcyte by 1.1% in the 3rd quarter. State Street Corp now owns 3,405,743 shares of the company's stock valued at $389,174,000 after buying an additional 38,596 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after buying an additional 324,560 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company's stock valued at $308,675,000 after buying an additional 259,010 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on PCVX shares. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $14.00 price target on shares of Vaxcyte in a research note on Tuesday. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $127.71.

Vaxcyte Stock Down 1.8 %

Shares of PCVX stock traded down $1.58 during trading hours on Thursday, reaching $83.84. 699,597 shares of the company's stock were exchanged, compared to its average volume of 1,118,568. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The stock has a market capitalization of $10.45 billion, a P/E ratio of -18.23 and a beta of 0.98. The business has a fifty day moving average price of $86.67 and a 200-day moving average price of $94.50.

Insider Transactions at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,735,022.90. The trade was a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total value of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares in the company, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,616 shares of company stock worth $6,095,681 over the last three months. 3.10% of the stock is currently owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.